RxDoctor Payments Data

Brian Leyland Jones

Medical Oncology · Sioux Falls, SDNPI 1174686547

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $336,245 of the $442,498 with a category attached, or 76.0%. 6 manufacturers reported payments, led by Genentech USA, Inc. at 44.7% of the total. Reporting peaked in 2019 at $237,124 and has fallen 84.0% since, to $37,829 in 2023.

$442,498in general payments, 2019–2025

Across 365 payments — averaging $1212.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$198K
  • Puma Biotechnology, Inc.$181K
  • Bayer$49K
  • Exelixis Inc.$9K
  • Ipsen Biopharmaceuticals, Inc$5K
  • Roche Molecular Systems, Inc.$400
$168,962in research payments, 2019–2025

Across 6 payments — averaging $28,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$160K
  • Puma Biotechnology, Inc.$5K
  • Tesaro, Inc.$4K

What the payments were for

  • Consulting fees$8,3802%
  • Speaking & faculty fees$336,24576%
  • Travel & lodging$92,12821%
  • Food & beverage$5,7451%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Other medical oncology in Sioux Falls

Where these figures come from

Is this you, or does something look wrong? →